MDR-1, but not MDR-3 gene expression, is associated with unmutated IgV_H genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia

References

• Gerlach J H, Kartner N, Bell D R, Ling V. Multidrug resistance. Cancer Surv 1986; 5: 25–46
   PubMedGoogle Scholar
• Gros P, Ben Neriah Y B, Croop J M, Housman D E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728–731
   PubMed Web of Science ®Google Scholar
• Holland K A, Holland I B. Adventures with ABC-proteins: highly conserved ATP-dependent transporters. Acta Microbiol Immunol Hung 2005; 52: 309–322
   PubMedGoogle Scholar
• Kartner N, Riordan J R, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285–1288
   PubMed Web of Science ®Google Scholar
• Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 774–780
   PubMed Web of Science ®Google Scholar
• Smith A J, de Vree J M, Ottenhoff R, Oude Elferink R P, Schinkel A H, Borst P. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (−/−) mice. Hepatology 1998; 28: 530–536
   PubMed Web of Science ®Google Scholar
• Smith A J, Timmermans-Hereijgers J L, Roelofsen B, Wirtz K W, van Blitterswijk W J, Smit J J, et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS 1994; 354: 263–266
   PubMed Web of Science ®Google Scholar
• van Helvoort A, Smith A J, Sprong H, Fritzsche I, Schinkel A H, Borst P, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87: 507–517
   PubMed Web of Science ®Google Scholar
• Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer H, et al. Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 1990; 45: 626–631
   PubMed Web of Science ®Google Scholar
• Larkin A, Moran E, Alexander D, Clynes M. Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias. Adv Exp Med Biol 1999; 457: 65–70
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Nooter K, Burghouts J T, Herweijer H, Adriaansen H J, van Dongen J J. High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496–1500
   PubMed Web of Science ®Google Scholar
• Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G, et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol 2004; 73: 407–411
   PubMed Web of Science ®Google Scholar
• Moran E, Larkin A, Doherty G, Kelehan P, Kennedy S, Clynes M. A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections. J Clin Pathol 1997; 50: 465–471
   PubMed Web of Science ®Google Scholar
• Larkin A, Moran E, Alexander D, Doherty G, Connolly L, Kennedy S M, Clynes M. A new monoclonal antibody that specifically recognises the MDR-3-encoded gene product. Int J Cancer 1999; 80: 265–271
   PubMed Web of Science ®Google Scholar
• van Dongen J J, Langerak A W, Bruggemann M, Evans P A, Hummel M, Lavender F L, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317
   PubMed Web of Science ®Google Scholar
• Matthews C, Catherwood M A, Morris T CM, Alexander H D. Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. Leuk Lymphoma 2004; 45: 1899–1904
   PubMed Web of Science ®Google Scholar
• Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar
• Austen B, Powell J E, Alvi A, Edwards I, Hooper L, Starczynski J, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175–3182
   PubMed Web of Science ®Google Scholar
• Stein U, Walther W, Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 1994; 30A: 1541–1545
   PubMed Web of Science ®Google Scholar
• Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol 1999; 457: 71–75
   PubMed Web of Science ®Google Scholar
• Arai Y, Masuda M, Sugawara I, Arai T, Motoji T, Tsuruo T, et al. Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Leuk Res 1997; 21: 313–319
   PubMed Web of Science ®Google Scholar
• el Rouby S, Thomas A, Costin D, Rosenberg C R, Potmesil M, Silber R, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwalkd M, et al. Activity of P-glycoprotein in B-cell chronic lymphocytic leukaemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751–1758
   PubMed Web of Science ®Google Scholar
• Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990; 82: 1133–1140
   PubMed Web of Science ®Google Scholar
• Wulf G, Kluding H, Ho A D, Doerner M, Doehner H, Manegold C, Hunstein W. Multidrug resistance phenotype in patients with chronic lymphocytic leukaemia as detected by immunofluorescence (FACS) and northern blot analysis. Leuk Res 1994; 18: 475–484
   PubMed Web of Science ®Google Scholar
• Friedenberg W R, Spencer S K, Musser C, Hogan T F, Rodvold K A, Rushing D A, et al. Multi-drug resistance in chronic lymphocytic leukaemia. Leuk Lymphoma 1999; 34: 171–178
   PubMed Web of Science ®Google Scholar
• Ganeshaguru K, Wickremasinghe R G, Jones D T, Gordon M, Hart S M, Virchis A E, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002; 87: 167–176
   PubMed Web of Science ®Google Scholar
• Galski H, Sivan H, Lazarovici P, Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: Implications on hematological malignancies. Leuk Res 2006; 30(9)1151–1158
   PubMed Web of Science ®Google Scholar